Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines

Kamińska, Joanna; Koper, Olga M.; Dymicka-Piekarska, Violetta; Motybel-Iwańczuk, Elżbieta; Ołdziej, Agnieszka Ewa; Kemona, H

doi:10.20452/pamw.3427

Cited by 10 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of new biomarkers predicting response to therapy would allow an identification of patients who should receive other first -line therapeutic regimens as the first -line treatment. [18][19][20] As in the previous reports, impaired renal function did not have negative impact on the response rates or PFS. Importantly, patients who responded to therapy showed an improvement in renal function, confirming the efficacy of this protocol in patients with renal failure.…”

supporting

confidence: 75%

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

Hus¹,

Walter‐Croneck²,

Masternak³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

supporting

confidence: 75%

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

Hus¹,

Walter‐Croneck²,

Masternak³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…The levels of serum soluble form of the cell-surface antigen BCMA [ 13 , 23 ], programmed death-ligand 1 (PD-L1) [ 6 ], IL-6 receptor (IL-6R) [ 24 ], CD40 ligand (CD40L) [ 25 ], and vascular cell adhesion molecule (VCAM)-1 [ 26 ] were shown to be increased in MM patients and associated with MM disease progression. In the present study, we demonstrated that sSLAMF7 levels were significantly elevated in advanced-stage MM patients, and the presence of sSLAMF7 in MM patients was also correlated with advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of serum soluble SLAMF7 in multiple myeloma

et al. 2018

View full text Add to dashboard Cite

The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients.

show abstract

“…The Youden index, a function of sensitivity and specificity, was estimated to indicate an optimal threshold value (cut-off point) for the parameters tested. The Youden index is a commonly used measure to evaluate the effectiveness of new biomarkers WHO World Health Organization, GFAP glial fibrillary acidic protein, p53 tumor protein p53, Ki-67 Ki-67 protein, EGFR epidermal growth factor receptor, IDH1 isocitrate dehydrogenase 1 and gives equal weight to sensitivity and specificity for the values of the biomarker tested [19].…”

Section: Csf and Serum Ccl2 Il-8 And Icam-1 Concentrations Evaluationmentioning

confidence: 99%

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

et al. 2017

View full text Add to dashboard Cite

Background The aim of the study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and sICAM-1 in patients with astrocytic tumors as compared to a group of non-tumoral patients. Methods Chemokine concentrations were measured using the ELISA method.Results Regardless of the parameter tested and the patient group (brain tumor or non-tumoral patients), statistical differences (P < 0.05) were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested. CSF IL-8 concentrations were significantly elevated in CNS tumor patients as compared to non-tumoral individuals (P = 0.000); serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors in comparison with the comparative group (P = 0.002 and P = 0.026, respectively). Among proteins tested in the serum, a higher area under the ROC curve (AUC) revealed CCL2 compared to sICAM-1 in differentiating subjects with CNS brain tumors from nontumoral subjects. AUC for CSF IL-8 was higher than for its index (CSF IL-8/serum IL-8).Conclusions For individual biomarkers (IL-8 and CCL2, sICAM-1), measured in CNS brain tumor patients, the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. Increased cerebrospinal fluid IL-8 with decreased serum CCL2 create a pattern of biomarkers, which may be helpful in the management of CNS astrocytic brain tumors.

show abstract

Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines

Cited by 10 publications

References 9 publications

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

Clinical impact of serum soluble SLAMF7 in multiple myeloma

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

Contact Info

Product

Resources

About